272 related articles for article (PubMed ID: 12825457)
21. Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.
Jaramillo C; de Diego JE; Hamdouchi C; Collins E; Keyser H; Sánchez-Martínez C; del Prado M; Norman B; Brooks HB; Watkins SA; Spencer CD; Dempsey JA; Anderson BD; Campbell RM; Leggett T; Patel B; Schultz RM; Espinosa J; Vieth M; Zhang F; Timm DE
Bioorg Med Chem Lett; 2004 Dec; 14(24):6095-9. PubMed ID: 15546737
[TBL] [Abstract][Full Text] [Related]
22. CDKs and CKIs: molecular targets for tissue remodelling.
Nabel EG
Nat Rev Drug Discov; 2002 Aug; 1(8):587-98. PubMed ID: 12402499
[TBL] [Abstract][Full Text] [Related]
23. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.
Lin R; Connolly PJ; Huang S; Wetter SK; Lu Y; Murray WV; Emanuel SL; Gruninger RH; Fuentes-Pesquera AR; Rugg CA; Middleton SA; Jolliffe LK
J Med Chem; 2005 Jun; 48(13):4208-11. PubMed ID: 15974571
[TBL] [Abstract][Full Text] [Related]
24. Genetic analysis of mammalian cyclin-dependent kinases and their inhibitors.
Malumbres M; Ortega S; Barbacid M
Biol Chem; 2000; 381(9-10):827-38. PubMed ID: 11076015
[TBL] [Abstract][Full Text] [Related]
25. Recent advances in the development of selective small molecule inhibitors for cyclin-dependent kinases.
Hirai H; Kawanishi N; Iwasawa Y
Curr Top Med Chem; 2005; 5(2):167-79. PubMed ID: 15853645
[TBL] [Abstract][Full Text] [Related]
26. Exploiting structural principles to design cyclin-dependent kinase inhibitors.
Noble M; Barrett P; Endicott J; Johnson L; McDonnell J; Robertson G; Zawaira A
Biochim Biophys Acta; 2005 Dec; 1754(1-2):58-64. PubMed ID: 16361058
[TBL] [Abstract][Full Text] [Related]
27. Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: new perspectives and therapeutic potential.
Andrés V
Cardiovasc Res; 2004 Jul; 63(1):11-21. PubMed ID: 15194457
[TBL] [Abstract][Full Text] [Related]
28. Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases.
Misra RN; Xiao HY; Williams DK; Kim KS; Lu S; Keller KA; Mulheron JG; Batorsky R; Tokarski JS; Sack JS; Kimball SD; Lee FY; Webster KR
Bioorg Med Chem Lett; 2004 Jun; 14(11):2973-7. PubMed ID: 15125971
[TBL] [Abstract][Full Text] [Related]
29. Small-molecule cyclin-dependent kinase modulators.
Senderowicz AM
Oncogene; 2003 Sep; 22(42):6609-20. PubMed ID: 14528286
[TBL] [Abstract][Full Text] [Related]
30. Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors.
Lee J; Choi H; Kim KH; Jeong S; Park JW; Baek CS; Lee SH
Bioorg Med Chem Lett; 2008 Apr; 18(7):2292-5. PubMed ID: 18353638
[TBL] [Abstract][Full Text] [Related]
31. Designing inhibitors of cyclin-dependent kinases.
Hardcastle IR; Golding BT; Griffin RJ
Annu Rev Pharmacol Toxicol; 2002; 42():325-48. PubMed ID: 11807175
[TBL] [Abstract][Full Text] [Related]
32. A putative role for cell cycle-related proteins in microtubule-based neuroplasticity.
Schmetsdorf S; Arnold E; Holzer M; Arendt T; Gärtner U
Eur J Neurosci; 2009 Mar; 29(6):1096-107. PubMed ID: 19302146
[TBL] [Abstract][Full Text] [Related]
33. Silymarin and silibinin cause G1 and G2-M cell cycle arrest via distinct circuitries in human prostate cancer PC3 cells: a comparison of flavanone silibinin with flavanolignan mixture silymarin.
Deep G; Singh RP; Agarwal C; Kroll DJ; Agarwal R
Oncogene; 2006 Feb; 25(7):1053-69. PubMed ID: 16205633
[TBL] [Abstract][Full Text] [Related]
34. Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases.
Hamdouchi C; Zhong B; Mendoza J; Collins E; Jaramillo C; De Diego JE; Robertson D; Spencer CD; Anderson BD; Watkins SA; Zhang F; Brooks HB
Bioorg Med Chem Lett; 2005 Apr; 15(7):1943-7. PubMed ID: 15780638
[TBL] [Abstract][Full Text] [Related]
35. Activity of substituted thiophene sulfonamides against malarial and mammalian cyclin dependent protein kinases.
Caridha D; Kathcart AK; Jirage D; Waters NC
Bioorg Med Chem Lett; 2010 Jul; 20(13):3863-7. PubMed ID: 20627564
[TBL] [Abstract][Full Text] [Related]
36. Cyclin-dependent kinase inhibitors: a survey of recent patent literature.
Galons H; Oumata N; Meijer L
Expert Opin Ther Pat; 2010 Mar; 20(3):377-404. PubMed ID: 20180621
[TBL] [Abstract][Full Text] [Related]
37. Current concepts in neuro-oncology: the cell cycle--a review.
Dirks PB; Rutka JT
Neurosurgery; 1997 May; 40(5):1000-13; discussion 1013-5. PubMed ID: 9149259
[TBL] [Abstract][Full Text] [Related]
38. Early development of cyclin dependent kinase modulators.
Roy KK; Sausville EA
Curr Pharm Des; 2001 Nov; 7(16):1669-87. PubMed ID: 11562305
[TBL] [Abstract][Full Text] [Related]
39. The cell cycle: a review of regulation, deregulation and therapeutic targets in cancer.
Vermeulen K; Van Bockstaele DR; Berneman ZN
Cell Prolif; 2003 Jun; 36(3):131-49. PubMed ID: 12814430
[TBL] [Abstract][Full Text] [Related]
40. Cyclin-dependent kinases as targets for cancer therapy.
Senderowicz AM
Cancer Chemother Biol Response Modif; 2002; 20():169-96. PubMed ID: 12703205
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
